1. Home
  2. ADVM vs MRBK Comparison

ADVM vs MRBK Comparison

Compare ADVM & MRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • MRBK
  • Stock Information
  • Founded
  • ADVM 2006
  • MRBK 2004
  • Country
  • ADVM United States
  • MRBK United States
  • Employees
  • ADVM N/A
  • MRBK N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • MRBK Major Banks
  • Sector
  • ADVM Health Care
  • MRBK Finance
  • Exchange
  • ADVM Nasdaq
  • MRBK Nasdaq
  • Market Cap
  • ADVM 119.6M
  • MRBK 159.8M
  • IPO Year
  • ADVM 2014
  • MRBK 2017
  • Fundamental
  • Price
  • ADVM $4.25
  • MRBK $14.39
  • Analyst Decision
  • ADVM Strong Buy
  • MRBK Buy
  • Analyst Count
  • ADVM 6
  • MRBK 2
  • Target Price
  • ADVM $27.83
  • MRBK $16.00
  • AVG Volume (30 Days)
  • ADVM 217.5K
  • MRBK 33.9K
  • Earning Date
  • ADVM 11-04-2024
  • MRBK 01-24-2025
  • Dividend Yield
  • ADVM N/A
  • MRBK 3.56%
  • EPS Growth
  • ADVM N/A
  • MRBK N/A
  • EPS
  • ADVM N/A
  • MRBK 1.00
  • Revenue
  • ADVM $1,000,000.00
  • MRBK $92,357,000.00
  • Revenue This Year
  • ADVM N/A
  • MRBK N/A
  • Revenue Next Year
  • ADVM $1,342.84
  • MRBK $10.48
  • P/E Ratio
  • ADVM N/A
  • MRBK $14.31
  • Revenue Growth
  • ADVM N/A
  • MRBK N/A
  • 52 Week Low
  • ADVM $4.01
  • MRBK $8.26
  • 52 Week High
  • ADVM $29.70
  • MRBK $17.33
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 29.33
  • MRBK 50.01
  • Support Level
  • ADVM $4.42
  • MRBK $13.56
  • Resistance Level
  • ADVM $5.11
  • MRBK $14.42
  • Average True Range (ATR)
  • ADVM 0.30
  • MRBK 0.41
  • MACD
  • ADVM 0.01
  • MRBK 0.02
  • Stochastic Oscillator
  • ADVM 21.05
  • MRBK 97.89

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

About MRBK Meridian Corporation

Meridian Corp is a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three business segments including Bank, Wealth, and Mortgage. It generates maximum revenue from the Bank segment that consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans, resulting in the generation of net interest income, and other sources.

Share on Social Networks: